Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by 4D Molecular Therapeutics, Inc. on May 23, 2023. The meeting was conducted virtually. As of the record date on March 28, 2023, there were 33,235,726 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
A total of 27,970,603 shares were voted in person or by proxy. The following proposals were approved:
- Proposal 1 (Election of Directors): Stockholders elected three Class III director nominees to serve until the 2026 Annual Meeting.
- Nancy Miller-Rich: 25,544,878 votes FOR; 648,302 votes WITHHELD.
- John F. Milligan, Ph.D.: 26,011,514 votes FOR; 181,666 votes WITHHELD.
- Shawn Cline Tomasello, MBA: 20,935,207 votes FOR; 5,257,973 votes WITHHELD.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Results: 27,957,650 votes FOR; 6,435 votes AGAINST; 6,518 votes ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the final composition of the Board of Directors following the election of the Class III nominees.
- Confirm the engagement of PricewaterhouseCoopers LLP for the 2023 fiscal year audit.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 12, 2023) for detailed background on the director nominees and auditor selection.